Phase 3 ALCANZA study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (Bex) in CD30-positive cutaneous T-cell lymphoma (CTCL): Number needed to treat analysis Meeting Abstract
| Authors: | Zagadailov, E.; Prince, H. M.; Whittaker, S.; Horwitz, S.; Duvic, M.; Kim, Y.; Dummer, R.; Scarisbrick, J.; Quaglino, P.; Zinzani, P. L.; Wolter, P.; Geskin, L.; Feliciano, J.; Wang, Y.; Palanca-Wessels, M. C.; Gautam, A.; Zhu, Y.; Lin, H. M.; Liu, Y.; Little, M.; Dalal, M. R. |
| Abstract Title: | Phase 3 ALCANZA study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (Bex) in CD30-positive cutaneous T-cell lymphoma (CTCL): Number needed to treat analysis |
| Meeting Title: | 22nd Congress of the European Hematology Association (EHA) |
| Journal Title: | Haematologica |
| Volume: | 102 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2017 Jun 22-25 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0390-6078 |
| Publisher: | Ferrata Storti Foundation |
| Date Published: | 2017-06-26 |
| Start Page: | 251 |
| Language: | English |
| ACCESSION: | WOS:000404127002128 |
| PROVIDER: | wos |
| PMCID: | PMC5492673 |
| Notes: | Meeting Abstract: P637 -- Source: Wos |
MSK Authors
-
645Horwitz